| Serum lipids in European chronic HCV genotype 1 patients during and after treatment with pegylated interferon-α-2a and ribavirin. | |
| | |
MedLine Citation:
|
PMID: 20729742 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
AIMS: Chronic hepatitis C alters the host's lipid metabolism and hepatitis C virus (HCV) eradication may be followed by an increase of serum cholesterol to adverse levels. We therefore aimed to determine the impact of chronic hepatitis C and its treatment on circulating lipids in a large European cohort of HCV genotype 1 patients. METHODS: The serum lipid profile of 575 HCV genotype 1-infected patients was characterized before, during and after treatment with pegylated interferon-α-2a (180 μg/week) and ribavirin (1000-1200 mg/day) for 48 weeks within a randomized controlled clinical trial. RESULTS: Total baseline cholesterol levels were significantly higher in patients with sustained virologic response (SVR) compared to nonresponders/relapsers (177 vs. 167 mg/dl, P=0.01), and low-cholesterol levels were an independent negative predictor of SVR (P=0.084). During the antiviral treatment, cholesterol levels substantially decreased as a putative marker of interferon-activity, but rebounded above baseline in patients with SVR (177-188 mg/dl, P=0.02), and to baseline in nonresponders/relapsers. Proportions of patients with cholesterol (>240 mg/dl) at baseline and after HCV eradication were 4 and 6%, respectively. Significant differences of triglyceride levels in patients with and without SVR were only observed at follow-up (136 and 117 mg/dl, respectively, P=0.028) but not at baseline. CONCLUSION: Our study reports a substantial pretreatment hypocholesterolemia in European HCV genotype 1 patients with nonresponse to interferon-α-based therapy and lower pretreatment cholesterol levels were an independent predictor of not attaining SVR. After treatment-induced HCV eradication median cholesterol levels increased above baseline, but the proportion of patients with high-risk cholesterol levels remained relatively low. |
| | |
Authors:
|
Christian M Lange; Michael von Wagner; Jörg Bojunga; Thomas Berg; Harald Farnik; Angela Hassler; Christoph Sarrazin; Eva Herrmann; Stefan Zeuzem |
Publication Detail:
|
Type: Journal Article; Multicenter Study; Randomized Controlled Trial |
Journal Detail:
|
Title: European journal of gastroenterology & hepatology Volume: 22 ISSN: 1473-5687 ISO Abbreviation: Eur J Gastroenterol Hepatol Publication Date: 2010 Nov |
Date Detail:
|
Created Date: 2010-10-15 Completed Date: 2011-02-02 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9000874 Medline TA: Eur J Gastroenterol Hepatol Country: England |
Other Details:
|
Languages: eng Pagination: 1303-7 Citation Subset: IM |
Affiliation:
|
Klinikum der J.W. Goethe-Universität Frankfurt am Main, Medizinische Klinik, Frankfurt am Main, Germany. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Antiviral Agents / therapeutic use* Biological Markers / blood Cholesterol / blood* Double-Blind Method Drug Therapy, Combination Europe Female Hepacivirus / genetics* Hepatitis C, Chronic / blood, complications, diagnosis, drug therapy* Humans Hypercholesterolemia / blood, virology* Interferon Alfa-2a / therapeutic use* Male Middle Aged Polyethylene Glycols / therapeutic use* Prospective Studies RNA, Viral / blood Ribavirin / therapeutic use* Time Factors Treatment Outcome Triglycerides / blood Viral Load Young Adult |
| Chemical | |
Reg. No./Substance:
|
0/Antiviral Agents; 0/Biological Markers; 0/Polyethylene Glycols; 0/RNA, Viral; 0/Triglycerides; 0/peginterferon alfa-2a; 36791-04-5/Ribavirin; 57-88-5/Cholesterol; 76543-88-9/Interferon Alfa-2a |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: BNP as marker of heart dysfunction in patients with liver cirrhosis.
Next Document: Primary sclerosing cholangitis complicated by amyloid A amyloidosis: complete regression of the neph...